An Exploratory Phase I, Randomized, Observer-blind, Placebo-controlled Dose Escalation Trial Evaluating the Safety, Tolerability and Immunogenicity of an Investigational RNA-based Vaccine for Active Immunization Against Malaria
Latest Information Update: 04 Oct 2024
At a glance
- Drugs BNT 165 (Primary)
- Indications Malaria
- Focus Adverse reactions; First in man
- Sponsors BioNTech
Most Recent Events
- 01 Oct 2024 Status changed from active, no longer recruiting to completed.
- 06 Apr 2023 Planned primary completion date changed from 1 Mar 2024 to 1 Feb 2024.
- 06 Apr 2023 Status changed from recruiting to active, no longer recruiting.